Analysis of Gastrointestinal Bleeding Treatment market covering 30 + countries including analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Projections for global gastrointestinal bleeding treatment market indicate a moderate growth rate of 5.1% during the forecast period (2020-2026). The market is set to surpass a value of US$ 849.79 by the end of 2026.
New product launches with technological enhancements have further augmented the market in the past. For instance, Cook Medical’s Hemospray, an endoscopic hemostat, received FDA approval in 2018 in line with gastrointestinal bleeding treatment guidelines.
The COVID-19 pandemic is poised to burgeon production of GI bleeding treatment products. Studies have proven that the COVID-19 virus affects the gastrointestinal tract of patients, causing diarrhea, nausea and vomiting. COVID-19 is soon emerging as one of the main gastrointestinal bleeding causes.
Don't Need a Global Report?
Save 40% on Country & Region specific reports
Endoscopic hemostasis has gained significant traction as an approach to treat GI bleeding. Established treatment modes include mechanical therapy, injection therapy and thermal therapy. The approach is well known for its ability to reduce mortality associated with GI bleeding.
Leading technological developments in development of hemostatic sprays and stents are being adopted to stop GI bleeding. This is expected to augment the gastrointestinal bleeding treatment market in the future.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Various technological advancements have streamlined the GI bleeding treatment market in the past few years. These include hemosprays, over-the-scope clips, padlock clips, radiofrequency ablation and self-expanding metal stents. Hemospray is a hemostatic powder developed by Cook Medical for treating gastrointestinal bleeding.
In recent years, transcatheter arterial embolization procedures have become the first-line therapy for managing upper GI bleeding that is refractory to endoscopic hemostasis. Advances in catheter-based techniques and newer embolic agents has broadened the scope of interventional radiology in managing hemorrhage. Transcatheter arterial embolization is effective for several indications. These include peptic ulcer bleeding, malignant diseases, and iatrogenic or trauma bleeding.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Endoscopic hemostatic devices are anticipated to account for more than half of the total gastrointestinal bleeding treatment market throughout the forecast period. Among these devices, the mechanical devices sub-segment is set to register maximum growth.
Increased usage of these devices for first line of treatment is a key driver behind the sub-segment’s growth. The Mechanical Devices sub-segment is set to expand at an impressive CAGR of 6.1% during the forecast period.
Upper GI Tract bleeding is one of the most prevalent symptoms of peptic ulcers. Other causes include esophageal varices, gastric varices, hemorrhagic gastritis and Mallory-Weiss syndrome. These conditions account for nearly 250,000 hospitalizations in the U.S. and over 300,000 in the U.K.
Based on peptic ulcers treatment trends, the upper GI tract segment is projected to capture more than 70% of the global GI bleeding treatment market. The segment shall expand at a CAGR of 4.8% during the forecast period.
At the same time, lower GI tract conditions such as diverticulosis, hemorrhoids, irritable bowel syndrome, colon polyps or cancer and vascular ectasia, have increased. This increasing prevalence of lower GI tract infections is anticipated to leverage market prospects.
The lower GI tract segment is anticipated to capture nearly three-tenths of the global gastrointestinal bleeding treatment market, expanding at a CAGR of 4.0% during the forecast period.
North America is set to retain hegemony over the gastrointestinal bleeding treatment market throughout the forecast period. The increasing hospitalization rate, strong presence of market leaders and product approvals such as the approval of Hemospray, are leading drivers of the burgeoning market share. Hemospray cost is also anticipated to be competitive in this region. Analysts project North America’s market share at over two-fifth of the total GI bleeding market.
Pursuing North America is Asia-Pacific, with a projected CAGR of 6% during the forecast period. Growth in the Asia-Pacific is attributed to increase in geriatric population, rise in prevalence of GI bleeding with age, and significant product launches and strategic acquisitions by leading market players. By 2026, Asia-Pacific is expected to surpass a valuation of US$ 96.2 Mn.
The global gastrointestinal bleeding treatment market is consolidated, with the presence of three major players contributing half of the total revenue. These companies are Boston Scientific Corporation, Cook Medical and Olympus Corporation.
Boston Scientific Corporation develops, markets and manufactures a wide range of products within the GI market. For instance, it manufactures Speedband Superview Super 7TM Multiple Band Ligator. This device is used for endoscopic ligation of esophageal varices and anorectal hemorrhoids.
Olympus Corporation, another market leader, concentrates on expansion of manufacturing facilities and leveraging healthcare awareness programs to stimulate early diagnosis of diseases. It focuses on reform and development activities related to medical systems across the world.
The COVID-19 pandemic has significant ramifications for gastrointestinal bleeding treatment market. Until recently, it was hypothesized that the COVID-19 virus primarily infects respiratory epithelial cells, and is transmitted via respiratory droplets.
However, several reports generated from a study conducted in February 2020 detected SARS-CoV-2 viral RNA in stool samples. Fecal occult blood testing indicated an upper gastrointestinal bleed in one of the patients.
Before the respiratory symptoms manifested, many patients reported severe cases of diarrhea, nausea, vomiting and abdominal discomfort. Therefore, it is imperative to safeguard GI disorders patients from the COVID-19 attack.
Important GI bleeding market players have thus streamlined their production in order to meet the burgeoning needs of healthcare providers. Erbe Elektromedizin GmBh, is ensuring security of supply so as not to experience any shortage of essential medical equipment. They have introduced shift-based operations to ensure sustainable production.
On a similar plane, Cook Medical has implemented shift changes and is closely monitoring its raw material supply chain. The company produces the Instinct TM Endoscopic Hemoclip, for the purpose of endoscopic marking and hemostasis for bleeding ulcers.
Moreover, hospitals, clinics, and other healthcare settings are engaged in simple management of endoscopes, endoscope reprocessing, and storage areas for gastrointestinal treatment purposes.
These include high-level disinfection through manual cleaning, reprocessing of endoscopes by experienced staff, and meticulous room cleaning post every procedure.
Leading manufacturers have invested heavily in introducing technological advancements in order to broad base their market presence. Moreover, the COVID-19 pandemic outbreak shall create an upsurge in the market, owing to recent studies concluding potential infections in the GI tract.
The recent study by Fact.MR on the global gastrointestinal bleeding treatment market provides a 6-year forecast on the key drivers, restraints and opportunities for expansion.
An in-depth analysis across various segments of the gastrointestinal bleeding treatment market has been incorporated in the report. Segmentation has been done on the basis of product, GI tract division and end-user. Each segment includes analysis based on revenue, market share and growth rate.
A detailed regional analysis has also been provided, based on the following five geographies: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa. Each region incorporates market analysis based on the segments highlighted above.
In addition, a section on the competitive landscape has also been provided, incorporating information on key market players, their strategies for expansion and an overview of their strengths, weaknesses, opportunities and threats.
Fact.MR has studied the gastrointestinal bleeding treatment market with detailed segmentation on the basis of product, GI tract division, end-users and key regions.
“This taxonomy prepared is confidential and intended exclusively for the individual or entity with whom it is being shared. Reading, disseminating, distributing, or copying this to any party other than the addressee(s) is unauthorized and prohibited.”
- Premium Report Details -
- Let's Connect -
- Quick Contact -
- Get Started -
Get insights that lead to new growth opportunitiesBuy Now
Get A Special pricing for start-ups and universitiesEnquiry Before Buying
- Humble, Yet Honored -
- Research Methodology -
An Adaptive Approach to Modern-day Research NeedsGet Methodology
The global gastrointestinal bleeding treatment market is set to grow steadily at 5.1% during the forecast.
Endoscopic hemostasis devices has gained significant traction to treat GI bleeding, capturing more than half of the total market share.
Hemosprays, over-the-scope clips, padlock clips, radiofrequency ablation, and self-expanding metal stents are the technological advancements in GI bleeding treatment.
Asia-Pacific region is expected to surpass a valuation of US$ 96.2 Million by 2026.
Need An Exclusive Report For Your Unique Requirement?